We are live on ! Find out more
PLXP

PLx Pharma Inc. Common Stock
PLXP

Delisted

PLXP was delisted on the 12th of April, 2023.

Back to rankings

14 hedge funds and large institutions have $17.7M invested in PLx Pharma Inc. Common Stock in 2014 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 1

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

12% more capital invested

Capital invested by funds: $15.8M → $17.7M (+$1.89M)

0% more funds holding

Funds holding: 14 → 14 (0)

Holders
14
Holders Change
–
Holders Change %
0%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
6
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AAP
Ardsley Advisory Partners
Connecticut
+$373K
2
KCM
Kingdon Capital Management
New York
+$213K
3
SIP
Stoneridge Investment Partners
Pennsylvania
+$121K
4
Vanguard Group
Vanguard Group
Pennsylvania
+$87.5K
5
TCM
Timpani Capital Management
Wisconsin
+$70.5K

Top Sellers

Rank Fund Capital Flow
1
PRCM
Pine River Capital Management
Minnesota
-$1.37M
2
Citigroup
Citigroup
New York
-$2K
3
FANJ
Financial Architects (New Jersey)
New Jersey
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
KCM
1
Kingdon Capital Management
New York
$8.31M +$213K +2,500 +3%
BC
2
Broadfin Capital
New York
$5.41M – – –
TCM
3
Timpani Capital Management
Wisconsin
$1.7M +$70.5K +827 +5%
PRCM
4
Pine River Capital Management
Minnesota
$880K -$1.37M -16,085 -62%
Vanguard Group
5
Vanguard Group
Pennsylvania
$419K +$87.5K +1,026 +29%
AAP
6
Ardsley Advisory Partners
Connecticut
$398K +$373K +4,375 New
OC
7
Oppenheimer & Co
New York
$271K +$34.8K +408 +16%
SIP
8
Stoneridge Investment Partners
Pennsylvania
$129K +$121K +1,413 New
Geode Capital Management
9
Geode Capital Management
Massachusetts
$124K – – –
Morgan Stanley
10
Morgan Stanley
New York
$13K +$5.46K +64 +85%
TRCT
11
Tower Research Capital (TRC)
New York
$7K +$4.26K +50 +200%
BIM
12
BlackRock Investment Management
Delaware
$6K – – –
Wells Fargo
13
Wells Fargo
California
$6K – – –
UBS Group
14
UBS Group
Switzerland
$6K +$5.37K +63 New
Citigroup
15
Citigroup
New York
– -$2K -25 Closed
FANJ
16
Financial Architects (New Jersey)
New Jersey
– -$1K -19 Closed

PLXP Hedge Fund Activity: Q4 2014 in Review

14 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in PLx Pharma Inc. Common Stock (PLXP) for Q4 2014, worth a combined $17.7M — up 12% from $15.8M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new PLXP positions and 2 closed out — a net gain of 1 holder — while 6 added to existing stakes and 1 trimmed.

The largest buyer was Ardsley Advisory Partners, opening a new position worth an estimated $373K. The largest seller was Pine River Capital Management, cutting an estimated $1.37M.

  • 14 institutional investors held PLx Pharma Inc. Common Stock (PLXP) as of Q4 2014, unchanged from Q3 2014.
  • Funds reported $17.7M of PLx Pharma Inc. Common Stock stock for Q4 2014, up 12% quarter-over-quarter.
  • 3 funds opened new PLx Pharma Inc. Common Stock positions in Q4 2014 and 2 closed out, a net change of +1 holder.
  • The largest PLx Pharma Inc. Common Stock buyer in Q4 2014 was Ardsley Advisory Partners, an estimated $373K added.
  • The largest PLx Pharma Inc. Common Stock seller in Q4 2014 was Pine River Capital Management, an estimated $1.37M sold.

Based on aggregated 13F filings for Q4 2014.